C82.3
Follicular lymphoma grade IIIa
Clinical Classification Guidelines
Medical Intelligence & Overview
Follicular lymphoma grade IIIa is a type of blood cancer that originates in the lymphatic system, specifically from B lymphocytes, which are a kind of white blood cell. It is classified as a non-Hodgkin lymphoma, characterized by the abnormal growth of lymphocyte cells that form in the lymph nodes and other lymphatic tissues. Being a more aggressive form within the follicular lymphoma spectrum, grade IIIa indicates a higher proliferation rate of these cancerous cells, often requiring specialized treatment approaches. Recognizing this diagnosis involves understanding its features, causes, symptoms, and management options.
Causes & Symptoms
Clinical Causes: Genetic mutations that lead to abnormal growth of lymphocytes A history of certain immune system conditions Age-related changes; most commonly diagnosed in older adults Potential environmental exposures, though specific causes are not well-defined Family history of lymphomas or other hematologic cancers
Key Symptoms: Swollen, painless lymph nodes in the neck, armpits, or groin Unexplained weight loss Fever that persists over time Night sweats Fatigue or weakness Feeling full without overeating due to enlarged lymph nodes pressing on the stomach Itching skin or skin rashes in some cases
Diagnostic & Treatment
Diagnosis Path: Physical examination to assess swollen lymph nodes and general health status Imaging tests such as CT scans, PET scans, or MRI to determine the extent of lymph node involvement Biopsy of affected lymph nodes to examine cell type and grade; in grade IIIa, a large number of follicular cells proliferate Immunophenotyping and molecular tests to identify specific markers on the cancer cells Bone marrow biopsy may be performed if spread is suspected
Treatment Protocols: Watchful waiting or observation for early or asymptomatic cases Chemotherapy regimens tailored to aggressive lymphomas, possibly including drugs like CHOP or CVP Immunotherapy with monoclonal antibodies such as rituximab Targeted therapies focusing on specific molecular pathways involved in lymphoma cell growth Radiation therapy in localized disease or for symptom relief Stem cell transplantation in selected cases to potentially achieve lasting remission Participation in clinical trials exploring new treatments or combination therapies
Clinical Advice & FAQs
Billing Guidance
Is C82.3 a billable ICD-10 code?
Yes, C82.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C82.3?
Clinical documentation must specify the nature of Follicular lymphoma grade IIIa and any associated comorbidities for accurate reporting.
Cite this Clinical Reference